莫西沙星在慢性阻塞性肺疾病急性加重期的應用進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

鄧聰 ,  曹曉紅

山西醫科大學（山西汾陽 030000）;

Corresponding?author：

曹曉紅, Email: caoxhong@sina.com

Keywords：

DOI：

10.7507/1671-6205.201902044

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 鄧聰, 曹曉紅. 莫西沙星在慢性阻塞性肺疾病急性加重期的應用進展. Chinese Journal of Respiratory and Critical Care Medicine, 2020, 19(4): 414-417. doi: 10.7507/1671-6205.201902044 Copy

1.	GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018[EB/OL]. [2018-07-17]. https://goldcoped.org/.
2.	Donaldson GC, Müllerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res, 2013, 14(1): 1-9.
3.	Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010, 363(12): 1128-1138.
4.	慢性阻塞性肺疾病急性加重(AECOPD)診治專家組. 慢性阻塞性肺疾病急性加重(AECOPD)診治中國專家共識(2017 年更新版). 國際呼吸雜志, 2017, 37(14): 1041-1057.
5.	劉麗, 張春燕, 邱鏃文. 慢性阻塞性肺疾病急性加重期呼吸道病毒感染檢出率及危險因素分析. 臨床肺科雜志, 2018, 23(6): 1118-1122.
6.	Alberto P, Cinzia MB, Fausto B, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 2006, 173(10): 1114-1121.
7.	Vollenweider DJ, Frei A, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2018, 10: CD010257.
8.	Woodhead M, Blasi F, Ewig S, et al. Guidelines for the Management of Adult Lower Respiratory Tract Infections. Clin Microbiol Infect, 2011, 17(s6): 1-24.
9.	Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006, 173(9): 991-998.
10.	肖琴鋒. COPD 患者下呼吸道感染的病原菌分布及耐藥性分析. 浙江臨床醫學, 2018, (1): 148-150.
11.	Sionidou M, Manika K, Pitsiou G, et al. Moxifloxacin in chronic obstructive pulmonary disease: pharmacokinetics and penetration into bronchial secretions in ward and intensive care unit patients. Antimicrob Agents Chemother, 2019, 63(3): 1974-1918.
12.	Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011, 365(8): 689-698.
13.	Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J, 2009, 34(5): 1066-1071.
14.	Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res, 2010, 11: 10.
15.	Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax, 2015, 70(10): 930-938.
16.	Schild K, Knobloch J, Yakin Y, et al. IL-5 release of CD4+ non-effector lymphocytes is increased in COPD--modulating effects of moxifloxacin and dexamethasone. Int Immunopharmacol, 2011, 11(4): 444-448.
17.	Chuchalin A, Zakharova M, Dokic D, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). BMC Pulm Med, 2013, 13: 5.
18.	Sethi S, Anzueto A, Miravitlles M, et al. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease. Infection, 2016, 44(1): 65-76.
19.	Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J, 2012, 40(1): 17-27.
20.	Minov J, Stoleski S, Petrova T, et al. Moxifloxacin in the outpatient treatment of moderate exacerbations of chronic obstructive pulmonary disease. Open Access Maced J Med Sci, 2018, 6(11): 2017-2022.
21.	Miravitlles M, Llor C, Molina J, et al. Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life. Int J Chron Obstruct Pulmon Dis, 2010, 5: 11-19.
22.	Miravitlles M, García-Polo C, Domenech A, et al. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung, 2013, 191(5): 523-530.
23.	Liu KX, Xu B, Wang J, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis, 2014, 6(3): 221-229.
24.	謝根英, 何拉結, 吳荔嘉, 等. 莫西沙星與左氧氟沙星分別治療慢性阻塞性肺疾病加重期療效與安全性的系統評價. 中國醫院用藥評價與分析, 2013, 13(7): 594-598.
25.	林其昌, 劉凱雄, 劉少濱, 等. 莫西沙星治療慢性阻塞性肺疾病急性加重療效和安全性的多中心研究. 中華結核和呼吸雜志, 2015, 38(5): 366-369.
26.	陳有娥. 哌拉西林鈉/他唑巴坦鈉聯合莫西沙星治療 COPD 合并急性下呼吸道感染的臨床觀察. 實用臨床醫藥雜志, 2015, 19(5): 18-21.
27.	伏俊, 房三友, 聞寅, 等. 美羅培南聯合莫西沙星治療慢性阻塞性肺病并發感染性肺炎的療效分析. 中華實驗和臨床感染病雜志(電子版), 2015, (1): 73-76.
28.	王媛媛, 劉麗萍, 操藝, 等. 莫西沙星序貫治療老年社區獲得性肺炎的藥物經濟學評價. 安徽醫藥, 2012, 16(2): 226-228.
29.	覃演秋. 霧化吸入莫西沙星治療慢性阻塞性肺疾病合并呼吸衰竭 92 例的臨床分析. 數理醫藥學雜志, 2015, (10): 1499-1500.

1. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018[EB/OL]. [2018-07-17]. https://goldcoped.org/.
2. Donaldson GC, Müllerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res, 2013, 14(1): 1-9.
3. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010, 363(12): 1128-1138.
4. 慢性阻塞性肺疾病急性加重(AECOPD)診治專家組. 慢性阻塞性肺疾病急性加重(AECOPD)診治中國專家共識(2017 年更新版). 國際呼吸雜志, 2017, 37(14): 1041-1057.
5. 劉麗, 張春燕, 邱鏃文. 慢性阻塞性肺疾病急性加重期呼吸道病毒感染檢出率及危險因素分析. 臨床肺科雜志, 2018, 23(6): 1118-1122.
6. Alberto P, Cinzia MB, Fausto B, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 2006, 173(10): 1114-1121.
7. Vollenweider DJ, Frei A, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2018, 10: CD010257.
8. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the Management of Adult Lower Respiratory Tract Infections. Clin Microbiol Infect, 2011, 17(s6): 1-24.
9. Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006, 173(9): 991-998.
10. 肖琴鋒. COPD 患者下呼吸道感染的病原菌分布及耐藥性分析. 浙江臨床醫學, 2018, (1): 148-150.
11. Sionidou M, Manika K, Pitsiou G, et al. Moxifloxacin in chronic obstructive pulmonary disease: pharmacokinetics and penetration into bronchial secretions in ward and intensive care unit patients. Antimicrob Agents Chemother, 2019, 63(3): 1974-1918.
12. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011, 365(8): 689-698.
13. Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J, 2009, 34(5): 1066-1071.
14. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res, 2010, 11: 10.
15. Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax, 2015, 70(10): 930-938.
16. Schild K, Knobloch J, Yakin Y, et al. IL-5 release of CD4+ non-effector lymphocytes is increased in COPD--modulating effects of moxifloxacin and dexamethasone. Int Immunopharmacol, 2011, 11(4): 444-448.
17. Chuchalin A, Zakharova M, Dokic D, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). BMC Pulm Med, 2013, 13: 5.
18. Sethi S, Anzueto A, Miravitlles M, et al. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease. Infection, 2016, 44(1): 65-76.
19. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J, 2012, 40(1): 17-27.
20. Minov J, Stoleski S, Petrova T, et al. Moxifloxacin in the outpatient treatment of moderate exacerbations of chronic obstructive pulmonary disease. Open Access Maced J Med Sci, 2018, 6(11): 2017-2022.
21. Miravitlles M, Llor C, Molina J, et al. Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life. Int J Chron Obstruct Pulmon Dis, 2010, 5: 11-19.
22. Miravitlles M, García-Polo C, Domenech A, et al. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung, 2013, 191(5): 523-530.
23. Liu KX, Xu B, Wang J, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis, 2014, 6(3): 221-229.
24. 謝根英, 何拉結, 吳荔嘉, 等. 莫西沙星與左氧氟沙星分別治療慢性阻塞性肺疾病加重期療效與安全性的系統評價. 中國醫院用藥評價與分析, 2013, 13(7): 594-598.
25. 林其昌, 劉凱雄, 劉少濱, 等. 莫西沙星治療慢性阻塞性肺疾病急性加重療效和安全性的多中心研究. 中華結核和呼吸雜志, 2015, 38(5): 366-369.
26. 陳有娥. 哌拉西林鈉/他唑巴坦鈉聯合莫西沙星治療 COPD 合并急性下呼吸道感染的臨床觀察. 實用臨床醫藥雜志, 2015, 19(5): 18-21.
27. 伏俊, 房三友, 聞寅, 等. 美羅培南聯合莫西沙星治療慢性阻塞性肺病并發感染性肺炎的療效分析. 中華實驗和臨床感染病雜志(電子版), 2015, (1): 73-76.
28. 王媛媛, 劉麗萍, 操藝, 等. 莫西沙星序貫治療老年社區獲得性肺炎的藥物經濟學評價. 安徽醫藥, 2012, 16(2): 226-228.
29. 覃演秋. 霧化吸入莫西沙星治療慢性阻塞性肺疾病合并呼吸衰竭 92 例的臨床分析. 數理醫藥學雜志, 2015, (10): 1499-1500.

Previous Article
腸道 EB 病毒相關淋巴組織增殖性疾病誤診為腸結核一例
Next Article
以機械功為導向的急性呼吸窘迫綜合征機械通氣新理念

Chinese Journal of Respiratory and Critical Care Medicine

莫西沙星在慢性阻塞性肺疾病急性加重期的應用進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content